Enovis (NYSE:ENOV) Issues Earnings Results

Enovis (NYSE:ENOV) issued its quarterly earnings data on Wednesday. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06, Zacks reports. The firm had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis updated its FY 2025 guidance to 3.100-3.250 EPS.

Enovis Price Performance

NYSE ENOV traded up $0.37 on Friday, hitting $38.49. 482,432 shares of the company were exchanged, compared to its average volume of 968,302. Enovis has a 1-year low of $37.60 and a 1-year high of $63.96. The company has a market cap of $2.19 billion, a P/E ratio of -17.56 and a beta of 1.94. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $44.81 and a two-hundred day moving average of $44.29.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC decreased their price target on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.